<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404389</url>
  </required_header>
  <id_info>
    <org_study_id>CLFX453X2201</org_study_id>
    <nct_id>NCT02404389</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients</brief_title>
  <official_title>A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Topical LFX453 Formulations in Patients With Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, vehicle controlled, active comparator, parallel group, study with a
      total duration of 24 weeks including screening and follow-up. Study drug is applied
      topically for 2 cycles of 4 week treatment, separated by 4 weeks off-treatment. Assessors of
      study endpoints are blinded to treatment allocation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events and local tolerability assessment scores as a measure of safety and tolerability</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of LFX453 compared to vehicle as measured by lesion count</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of LFX453 in skin samples and blood samples after application</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of LFX453 compared to vehicle at week 8 and week 16 as measured by lesion count</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LFX453 CSF1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFX453 CSF2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle CSF1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle CSF2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aldara</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 applications per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigational Treatment</intervention_name>
    <description>Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.</description>
    <arm_group_label>LFX453 CSF1</arm_group_label>
    <arm_group_label>LFX453 CSF2</arm_group_label>
    <arm_group_label>Vehicle CSF1</arm_group_label>
    <arm_group_label>Vehicle CSF2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator</intervention_name>
    <description>Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.</description>
    <arm_group_label>Aldara</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least five (5) AK lesions within an area of 25 cm2, on the face (at least 2 cm
             from the periocular areas, lips, nares and ears) and/or balding scalp

        Presence of at least one additional visible or palpable non hyperkeratotic AK lesion
        outside of the selected area

        Exclusion Criteria:

          -  atopic dermatitis, eczema, psoriasis, rosacea or other possible confounding skin
             conditions on face or balding scalp Invasive tumors within the treatment area Women
             of child-bearing potential

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A 1040</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>IS-201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 8, 2016</lastchanged_date>
  <firstreceived_date>January 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratosis, patients, topical, lesion count, clearance rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
